Kala reaches deal to sell Eysuvis, Inveltys to Alcon
May 23, 2022
According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Clinical Diagnosis
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
May 24, 2022
The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease
Ophthalmologists drive efficiency in the surgical suite: Why it matters
May 23, 2022
Attention to details can help to deliver patients consistent, quality outcomes.
The effects of unilateral congenital ptosis in a pediatric population
May 23, 2022
Clinicians discover the ptotic facial side of the face was the nondominant side of the face in a recent study.
Blog: A new era for refractive surgery in the United States: STAAR EVO ICL wins FDA approval
May 22, 2022
There’s a new alternative to LASIK in the United States. In March of 2022, the FDA approved STAAR Surgical’s EVO/EVO+ VISIAN Implantable Collamer Lens (ICL) and Toric Implantable Collamer Lens (TICL).
Dr. Pomerance: How the mix of medicine and surgery attracted him to ophthalmology
May 20, 2022
Tennessee Academy of Ophthalmology’s doctor of the month shares what excites him about ophthalmology, his biggest career challenge, and chocolate as his favorite comfort food.
Five new aqueous humor biomarkers of POAG progression are identified
May 19, 2022
Investigators find the recognition could improve surveillance of the disease.
Retinal cell map could advance precise therapies for blinding diseases
May 14, 2022
A discovery by investigators at the National Eye Institute sheds light on tissue targeted by age-related macular degeneration and other diseases.
VLRC Eye Van making 50th anniversary tour
May 14, 2022
The Eye Van, operated by Vision Loss Rehabilitation Canada, is a mobile medical clinic that delivers eye care in northern Ontario communities where ophthalmology services aren't readily available.
MacuLogix reaches milestone with 1 million dark adaptation tests
May 12, 2022
As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.
Latest News
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue